You are directing your anger at the wrong guy, and rockford is also. The BOD is in a difficult position and the only sure thing they can do is raise the book value of the company, that will raise the offer level but that will further infuriate the small shareholder base that numbers about 4500 street name people. They will get into a fury over dilution.

Alternatively they can counter any offer and that may buy time. Hiring an expert, in my opinion, might be a trigger for a tender. A valuation expert will take 3-4 weeks to write his report. If GenPrecis product is the reason the company is in play, then the acquisition partner may not wish to wait and would go directly to the shareholder base. And in my opinion 51% of the outstanding shares would take an offer of $0.25. I hope I'm wrong, but I also feel that many would take less and that's how tenders work.

In the end, if there is an end, it will be your shareholder colleagues that sell you out, not me.